|
1
|
Vandenberghe H; Second MIC Cooperative
Study Group, : Morphologic, immunologic and cytogenetic (MIC)
working classification of the acute myeloid leukaemias. Br J
Haematol. 68:487–494. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Head DR: Revised classification of acute
myeloid leukemia. Leukemia. 10:1826–1831. 1996.PubMed/NCBI
|
|
3
|
Ravindranath Y, Chang M, Steuber CP,
Becton D, Dahl G, Civin C, Camitta B, Carroll A, Raimondi SC and
Weinstein HJ; Pediatric Oncology Group, : Pediatric Oncology Group
(POG) studies of acute myeloid leukemia (AML): A review of four
consecutive childhood AML trials conducted between 1981 and 2000.
Leukemia. 19:2101–2116. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smith FO, Alonzo TA, Gerbing RB, Woods WG,
Arceci RJ and Grp Cs C; Children's Cancer Group, : Long-term
results of children with acute myeloid leukemia: a report of three
consecutive Phase III trials by the Children's Cancer Group: CCG
251, CCG 213 and CCG 2891. Leukemia. 19:2054–2062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Estey EH: How I treat older patients with
AML. Blood. 96:1670–1673. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cummins JM and Velculescu VE: Implications
of micro-RNA profiling for cancer diagnosis. Oncogene.
25:6220–6227. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumar MS, Lu J, Mercer KL, Golub TR and
Jacks T: Impaired microRNA processing enhances cellular
transformation and tumorigenesis. Nat Genet. 39:673–677. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gregory RI and Shiekhattar R: MicroRNA
biogenesis and cancer. Cancer Res. 65:3509–3512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Silakit R, Loilome W, Yongvanit P, Chusorn
P, Techasen A, Boonmars T, Khuntikeo N, Chamadol N, Pairojkul C and
Namwat N: Circulating miR-192 in liver fluke-associated
cholangiocarcinoma patients: A prospective prognostic indicator. J
Hepatobiliary Pancreat Sci. 21:864–872. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang LG and Gu J: Serum microRNA-29a is a
promising novel marker for early detection of colorectal liver
metastasis. Cancer Epidemiol. 36:e61–e67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ng EKO, Chong WWS, Jin H, Lam EK, Shin VY,
Yu J, Poon TC, Ng SS and Sung JJ: Differential expression of
microRNAs in plasma of patients with colorectal cancer: A potential
marker for colorectal cancer screening. Gut. 58:1375–1381. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen P, Price C, Li Z, Li Y, Cao D, Wiley
A, He C, Gurbuxani S, Kunjamma RB, Huang H, et al: miR-9 is an
essential oncogenic microRNA specifically overexpressed in mixed
lineage leukemia-rearranged leukemia. Proc Natl Acad Sci USA.
110:11511–11516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li C, Yan H, Yin J, Ma J, Liao A, Yang S,
Wang L, Huang Y, Lin C, Dong Z, et al: MicroRNA-21 promotes
proliferation in acute myeloid leukemia by targeting Krüppel-like
factor 5. Oncol Lett. 18:3367–3372. 2019.PubMed/NCBI
|
|
19
|
Liu L, Ren W and Chen K: MiR-34a promotes
apoptosis and inhibits autophagy by targeting HMGB1 in acute
myeloid leukemia cells. Cell Physiol Biochem. 41:1981–1992. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
de Leeuw DC, Denkers F, Olthof MC, Rutten
AP, Pouwels W, Schuurhuis GJ, Ossenkoppele GJ and Smit L:
Attenuation of microRNA-126 expression that drives
CD34+38− stem/progenitor cells in acute
myeloid leukemia leads to tumor eradication. Cancer Res.
74:2094–2105. 2014. View Article : Google Scholar
|
|
21
|
Hartmann JU, Brauer-Hartmann D, Kardosova
M, Wurm AA, Wilke F, Schödel C, Gerloff D, Katzerke C, Krakowsky R,
Namasu CY, et al: MicroRNA-143 targets ERK5 in granulopoiesis and
predicts outcome of patients with acute myeloid leukemia. Cell
Death Dis. 9:8142018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wallace JA, Kagele DA, Eiring AM, Kim CN,
Hu R, Runtsch MC, Alexander M, Huffaker TB, Lee SH, Patel AB, et
al: miR-155 promotes FLT3-ITD-induced myeloproliferative disease
through inhibition of the interferon response. Blood.
129:3074–3086. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu ZL, Wang H, Liu J and Wang ZX:
MicroRNA-21 (miR-21) expression promotes growth, metastasis, and
chemo- or radioresistance in non-small cell lung cancer cells by
targeting PTEN. Mol Cell Biochem. 372:35–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu Y, Han Y, Tian T, Su P, Jin G, Chen J
and Cao Y: MiR-21-5p, miR-34a, and human telomerase RNA component
as surrogate markers for cervical cancer progression. Pathol Res
Pract. 214:374–379. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Okugawa Y, Yao L, Toiyama Y, Yamamoto A,
Shigemori T, Yin C, Omura Y, Ide S, Kitajima T, Shimura T, et al:
Prognostic impact of sarcopenia and its correlation with
circulating miR-21 in colorectal cancer patients. Oncol Rep.
39:1555–1564. 2018.PubMed/NCBI
|
|
26
|
Chen S, Chen X, Shan T, Ma J, Lin W, Li W
and Kang Y: MiR-21-mediated Metabolic Alteration of
Cancer-associated Fibroblasts and Its Effect on Pancreatic Cancer
Cell Behavior. Int J Biol Sci. 14:100–110. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luo F, Ji J, Liu Y, Xu Y, Zheng G, Jing J,
Wang B, Xu W, Shi L, Lu X, et al: MicroRNA-21, up-regulated by
arsenite, directs the epithelial-mesenchymal transition and
enhances the invasive potential of transformed human bronchial
epithelial cells by targeting PDCD4. Toxicol Lett. 232:301–309.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang Q, Xu E, Dai J, Wu J, Zhang S, Peng B
and Jiang Y: miR-21 regulates
N-methyl-N-nitro-N′-nitrosoguanidine-induced gastric tumorigenesis
by targeting FASLG and BTG2. Toxicol Lett. 228:147–156. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang G, Wang JJ, Tang HM and To SS:
Targeting strategies on miRNA-21 and PDCD4 for glioblastoma. Arch
Biochem Biophys. 580:64–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fu X, Han Y, Wu Y, Zhu X, Lu X, Mao F,
Wang X, He X and Zhao Y and Zhao Y: Prognostic role of microRNA-21
in various carcinomas: A systematic review and meta-analysis. Eur J
Clin Invest. 41:1245–1253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Asangani IA, Rasheed SAK, Nikolova DA,
Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and
stimulates invasion, intravasation and metastasis in colorectal
cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Espadinha AS, Prouzet-Mauléon V, Claverol
S, Lagarde V, Bonneu M, Mahon FX and Cardinaud B: A tyrosine
kinase-STAT5-miR21-PDCD4 regulatory axis in chronic and acute
myeloid leukemia cells. Oncotarget. 8:76174–76188. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ruiz-Lafuente N, Alcaraz-Garcia MJ,
Sebastian-Ruiz S, García-Serna AM, Gómez-Espuch J, Moraleda JM,
Minguela A, García-Alonso AM and Parrado A: IL-4 up-regulates
MiR-21 and the MiRNAs hosted in the CLCN5 gene in chronic
lymphocytic leukemia. Plos One. 10:e01249362015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Taverna S, Giallombardo M, Pucci M, Flugy
A, Manno M, Raccosta S, Rolfo C, De Leo G and Alessandro R:
Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia
cells growth: A possible role for exosomal disposal of miR-21.
Oncotarget. 6:21918–21933. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Labib HA, Elantouny NG, Ibrahim NF and
Alnagar AA: Upregulation of microRNA-21 is a poor prognostic marker
in patients with childhood B cell acute lymphoblastic leukemia.
Hematology. 22:392–397. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Riccioni R, Lulli V, Castelli G, Biffoni
M, Tiberio R, Pelosi E, Lo-Coco F and Testa U: miR-21 is
overexpressed in NPM1-mutant acute myeloid leukemias. Leuk Res.
39:221–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu P, Li P and Burke S: Critical roles of
Bcl11b in T-cell development and maintenance of T-cell identity.
Immunol Rev. 238:138–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wakabayashi Y, Inoue J, Takahashi Y,
Matsuki A, Kosugi-Okano H, Shinbo T, Mishima Y, Niwa O and Kominami
R: Homozygous deletions and point mutations of the Rit1/Bcl11b gene
in gamma-ray induced mouse thymic lymphomas. Biochem Biophys Res
Commun. 301:598–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Abbas S, Sanders MA, Zeilemaker A,
Geertsma-Kleinekoort WM, Koenders JE, Kavelaars FG, Abbas ZG,
Mahamoud S, Chu IW, Hoogenboezem R, et al: Integrated genome-wide
genotyping and gene expression profiling reveals BCL11B as a
putative oncogene in acute myeloid leukemia with 14q32 aberrations.
Haematologica. 99:848–857. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Landgraf P, Rusu M, Sheridan R, Sewer A,
Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M,
et al: A mammalian microRNA expression atlas based on small RNA
library sequencing. Cell. 129:1401–1414. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
National Cancer Institute, . The Cancer
Genome Atlas Program. Accessed from:. simplehttp://cancergenome.nih.gov/publications/publicationguidelines
|
|
42
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Morris GF and Mathews MB: Regulation of
proliferating cell nuclear antigen during the cell cycle. J Biol
Chem. 264:13856–13864. 1989.PubMed/NCBI
|
|
44
|
Zhong W, Peng J, He H, Wu D, Han Z, Bi X
and Dai Q: Ki-67 and PCNA expression in prostate cancer and benign
prostatic hyperplasia. Clin Invest Med. 31:E8–E15. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Juríková M, Danihel Ľ, Polák Š and Varga
I: Ki67, PCNA, and MCM proteins: Markers of proliferation in the
diagnosis of breast cancer. Acta Histochem. 118:544–552. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kimos MC, Wang S, Borkowski A, Yang GY,
Yang CS, Perry K, Olaru A, Deacu E, Sterian A, Cottrell J, et al:
Esophagin and proliferating cell nuclear antigen (PCNA) are
biomarkers of human esophageal neoplastic progression. Int J
Cancer. 111:415–417. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Obata M, Kominami R and Mishima Y: BCL11B
tumor suppressor inhibits HDM2 expression in a p53-dependent
manner. Cell Signal. 24:1047–1052. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li Y, Li W, Yang Y, Lu Y, He C, Hu G, Liu
H, Chen J, He J and Yu H: MicroRNA-21 targets LRRFIP1 and
contributes to VM-26 resistance in glioblastoma multiforme. Brain
Res. 1286:13–18. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li T, Li D, Sha J, Sun P and Huang Y:
MicroRNA-21 directly targets MARCKS and promotes apoptosis
resistance and invasion in prostate cancer cells. Biochem Biophys
Res Commun. 383:280–285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kimura S, Naganuma S, Susuki D, Hirono Y,
Yamaguchi A, Fujieda S, Sano K and Itoh H: Expression of microRNAs
in squamous cell carcinoma of human head and neck and the
esophagus: MiR-205 and miR-21 are specific markers for HNSCC and
ESCC. Oncol Rep. 23:1625–1633. 2010.PubMed/NCBI
|
|
51
|
Volinia S, Galasso M, Costinean S,
Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N,
Sana ME, Abu Jarour R, et al: Reprogramming of miRNA networks in
cancer and leukemia. Genome Res. 20:589–599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pichiorri F, Suh SS, Ladetto M, Kuehl M,
Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, et
al: MicroRNAs regulate critical genes associated with multiple
myeloma pathogenesis. Proc Natl Acad Sci USA. 105:12885–12890.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fulci V, Chiaretti S, Goldoni M, Azzalin
G, Carucci N, Tavolaro S, Castellano L, Magrelli A, Citarella F,
Messina M, et al: Quantitative technologies establish a novel
microRNA profile of chronic lymphocytic leukemia. Blood.
109:4944–4951. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Asangani IA, Rasheed SAK, Nikolova DA,
Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and
stimulates invasion, intravasation and metastasis in colorectal
cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
He C, Dong X, Zhai B, Jiang X, Dong D, Li
B, Jiang H, Xu S and Sun X: MiR-21 mediates sorafenib resistance of
hepatocellular carcinoma cells by inhibiting autophagy via the
PTEN/Akt pathway. Oncotarget. 6:28867–28881. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lee BS, Dekker JD, Lee BK, Iyer VR,
Sleckman BP, Shaffer AL III, Ippolito GC and Tucker PW: The BCL11A
transcription factor directly activates RAG gene expression and
V(D)J recombination. Mol Cell Biol. 33:1768–1781. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cismasiu VB, Adamo K, Gecewicz J, Duque J,
Lin Q and Avram D: BCL11B functionally associates with the NuRD
complex in T lymphocytes to repress targeted promoter. Oncogene.
24:6753–6764. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wu H, Pomeroy SL, Ferreira M, Teider N,
Mariani J, Nakayama KI, Hatakeyama S, Tron VA, Saltibus LF,
Spyracopoulos L, et al: UBE4B promotes Hdm2-mediated degradation of
the tumor suppressor p53. Nat Med. 17:347–355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kubbutat MH, Jones SN and Vousden KH:
Regulation of p53 stability by Mdm2. Nature. 387:299–303. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Go R, Takizawa K, Hirose S, Katsuragi Y,
Aoyagi Y, Mishima Y and Kominami R: Impairment in differentiation
and cell cycle of thymocytes by loss of a Bcl11b tumor suppressor
allele that contributes to leukemogenesis. Leuk Res. 36:1035–1040.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kamimura K, Mishima Y, Obata M, Endo T,
Aoyagi Y and Kominami R: Lack of Bcl11b tumor suppressor results in
vulnerability to DNA replication stress and damages. Oncogene.
26:5840–5850. 2007. View Article : Google Scholar : PubMed/NCBI
|
